Getinge finalizes the acquisition of Atrium Medical Inc. and changes the date of its AGM

Getinge finalizes the acquisition of Atrium Medical Inc. and changes the
date of its AGM

Getinge receives approval of the relevant anti-trust bodies and
finalizes the acquisition of Atrium Medical Inc.

Getinge, 7 November, 2011

Getinge has been granted the approval of US anti-trust authority FTC
(Federal Trade Commission) to go ahead with the acquisition of Atrium
Medical Inc. The acquisition was finalized on 4 November, 2011, and will
be consolidated in Getinge's accounts as of 1 November this year.

Atrium Medical has exclusively grown organically since its inception. In
the past five-year period, Atrium Medical has grown an average of 19%
annually and its sales are expected to reach slightly more than USD 200
million in the current calendar year. Atrium Medical's headquarters,
including product development and production, are based in Hudson, New
Hampshire, in the US. Atrium Medical sells its products through
proprietary sales offices in the US, the UK, Germany, France, the
Netherlands, India, Australia and New Zealand. In addition to direct
sales through proprietary market companies, Atrium Medical's products
are also sold through a network of international distributors. For the
current year, sales to customers outside the US are expected to account
for 30% of overall sales. Atrium Medical has about 700 employees
worldwide.

Atrium Medical's product programme is primarily geared toward the
cardiovascular market and encompasses cardio-thoracic drainage products,
vascular grafts, balloon expandable covered stents, thrombus management
catheters and biosurgery products. Atrium Medical has a strong pipeline
of new products for the coming years, which are largely based on the
company's know-how and extensive expertise in the deployment of ePTFE in
medical-technical applications.

The purchase consideration for Atrium Medical amounts to USD 680 million
(Enterprise Value), corresponding to an EV/EBIT multiple of 12.8 based
on expected earnings in 2012. Atrium Medical is expected to be able to
continue expanding rapidly in line with its growth in recent years, and
will benefit from Getinge's existing sales organisation, which features
proprietary representation in a significant number of markets in which
the company is not currently active. Excluding acquisition-related costs
of about USD 6 million, which will be charged to the fourth quarter of
2011, and excluding restructuring costs of about USD 8 million, the
acquisition is expected to contribute somewhat to the Group's earnings
per share in 2012. As of 2013, the contribution to the Group's earnings
per share is expected to rise rapidly.

Getinge changes AGM date
Getinge AB's AGM will be held at 2 p.m. on 28 March 2012 in the Congress
Hall in Hotel Tylösand, Halmstad. Any shareholders who wish to have an
issue raised at the AGM on 29 March 2012 should submit their request to
Getinge's Board Chairman via e-mail to: arenden.bolagsstamma@getinge.com
or by mail to Getinge AB Attn: Bolagsstämmoärenden, Box 69, 305 05
GETINGE, Sweden. To be certain of being included in the AGM agenda, the
request must arrive at the company no later than Wednesday 1 February,
2012.

For further information, contact:

Ulf Grunander

CFO
Tel.:+46  (0) 103 35 55 80
E-mail: ulf.grunander@getinge.com (ulf.grunander@getinge.com)

GETINGE GROUP is a leading global provider of products and systems that
contribute to quality enhancement and cost efficiency within healthcare
and life sciences. We operate under the three brands of ArjoHuntleigh,
GETINGE and MAQUET. ArjoHuntleigh focuses on patient mobility and wound
management solutions. GETINGE provides solutions for infection control
within healthcare and contamination prevention within life sciences.
MAQUET specializes in solutions, therapies and products for surgical
interventions and intensive care.